Last reviewed 2026-04-20 · How we verify

PENTETATE INDIUM DISODIUM IN 111

FDA-approved approved Small molecule Quality 0/100

PENTETATE INDIUM DISODIUM IN 111 is a drug. It is currently FDA-approved (first approved 1982).

Pentetate Indium Disodium in 111 is a marketed radiopharmaceutical with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	PENTETATE INDIUM DISODIUM IN 111
Modality	Small molecule
Phase	FDA-approved
First approval	1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PENTETATE INDIUM DISODIUM IN 111 CI brief — competitive landscape report
PENTETATE INDIUM DISODIUM IN 111 updates RSS · CI watch RSS

Frequently asked questions about PENTETATE INDIUM DISODIUM IN 111

What is PENTETATE INDIUM DISODIUM IN 111?

PENTETATE INDIUM DISODIUM IN 111 is a Small molecule drug.

When was PENTETATE INDIUM DISODIUM IN 111 approved?

PENTETATE INDIUM DISODIUM IN 111 was first approved on 1982.

What development phase is PENTETATE INDIUM DISODIUM IN 111 in?

PENTETATE INDIUM DISODIUM IN 111 is FDA-approved (marketed).

Compare: PENTETATE INDIUM DISODIUM IN 111 vs similar drugs
Pricing: PENTETATE INDIUM DISODIUM IN 111 cost, discount & access